23
Participants
Start Date
July 2, 2013
Primary Completion Date
April 23, 2014
Study Completion Date
April 23, 2014
18 F-FP-DTBZ
The drug, no carrier added \[18 F\]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce \[18 F\]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 millicuries (mCi) of \[18 F\]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
PET Scanning
Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
Naomi Berrie Diabetes Center, New York
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Columbia University
OTHER